The University of Tokyo · Medicine
Professor Satoru Taguchi's research lab focuses on marine biogeochemistry and oncology, with key research directions including lipid metabolism in marine diatoms under nutrient-limited conditions and the development of oncolytic virus therapies for cancer treatment. The lab investigates how environmental factors such as silicate availability influence lipid production in diatoms, contributing to understanding marine carbon cycling. Concurrently, it explores the clinical potential of oncolytic viruses like T-VEC and Pexa-Vec in treating urological cancers, particularly metastatic urothelial carcinoma, with a focus on prognostic biomarkers and imaging-based diagnostics. The integration of molecular oncology with clinical imaging and biomarker discovery defines the lab’s translational research approach.
Figures are computed from collected data and may differ slightly.
ABSTRACT Lipid synthesis of three marine diatoms was studied with a 14 CO 2 incorporation technique in silicate limited batch cultures. Growth rates were independent of the silicate concentration but the cellular yields were proportional to the initial amount of silicate. At the beginning of the stationary growth phase, lipid synthesis rates per unit culture volume increased by 1.7 times for Chaetoceros gracilis, 3.1 times for Hantzschia sp., and 2.8 times for Cyclotella sp., respectively compar
Oncolytic virus therapy is a promising new option for cancer. It utilizes genetically engineered or naturally occurring viruses that selectively replicate in and kill cancer cells without harming normal cells. T-VEC (talimogene laherparepvec), a second-generation oncolytic herpes simplex virus type 1, was approved by the US Food and Drug Administration for the treatment of inoperable melanoma in 2015 and subsequently approved in Europe in 2016. Other oncolytic viruses using different parental vi
Oncolytic virus therapy has recently been recognized as a promising new option for cancer treatment. Oncolytic viruses replicate selectively in cancer cells, thus killing them without harming normal cells. Notably, T-VEC (talimogene laherparepvec, formerly called OncoVEX<sup>GM</sup><sup>-</sup><sup>CSF</sup> ), an oncolytic herpes simplex virus type 1, was approved by the US Food and Drug Administration for the treatment of inoperable melanoma in October 2015, and was subsequently approved in E
Pretreatment neutrophil-to-lymphocyte ratio elevation was an independent poor prognostic factor for metastatic urothelial carcinoma undergoing salvage chemotherapy. Our newly constructed prognostic model including the pretreatment neutrophil-to-lymphocyte ratio proved to be an excellent discriminator of overall survival.
Liver metastasis, poor performance status and higher leukocyte counts were independent poor prognostic indicators for metastatic urothelial carcinoma. Our risk classification enables an accurate prediction of survival that can be useful in deciding which patients are likely to benefit from salvage chemotherapy.
In this prospective validation study with a next-generation magnetic resonance imaging scanner, VI-RADS showed high predictive accuracy for muscle invasion in patients with bladder cancer before transurethral resection of bladder tumor. Combining T2-weighted imaging with denoising deep learning reconstruction might further improve the diagnostic accuracy of VI-RADS.
Although the albumin-to-globulin ratio (AGR) is a promising biomarker, no study has investigated its prognostic significance for advanced urothelial carcinoma (UC). This study conformed to the REporting recommendations for tumor MARKer prognostic studies (REMARK) criteria. We retrospectively reviewed 176 patients with advanced UC treated with pembrolizumab between 2018 and 2020. We evaluated the associations between pretreatment clinicopathological variables, including the AGR and performance st
Open papers in the app to read, cite, and organize with AI.
